Quantum BioPharma LtdCanadian Securities Exchange:QNTMView on NASDAQ
- LAST PRICE7.0000
- TODAY'S CHANGE (%)-0.0500 (-0.7092%)
- Bid / Lots7.0000/ 1
- Ask / Lots7.5000/ 5
- Open / Previous Close7.0000 / 7.0500
- Day Range
- 52 Week Range
- Volume101
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | QNTM |
|---|---|---|
| 02:02 ET | 100 | 7 |
| 04:00 ET | 300 | 7 |
Oct 29, 2024
Oct 28, 2024
Christian Attar Files Market Manipulation Case On Behalf of Quantum Biopharma, from 11:10AM ET on Monday Oct 28, 2024 by Dow Jones
11:10AM ET on Monday Oct 28, 2024 by Dow Jones
Oct 23, 2024
Freedman Normand Friedland Files Market Manipulation Case On Behalf of Quantum Biopharma, from 9:30AM ET on Wednesday Oct 23, 2024 by Dow Jones
9:30AM ET on Wednesday Oct 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Quantum BioPharma Ltd | 13.5M | -0.3x | --- |
Sirona Biochem Corp | 19.7M | -7.2x | --- |
BioMark Diagnostics Inc | 20.0M | -9.6x | --- |
Biovaxys Technology Corp | 17.0M | -2.4x | --- |
Resverlogix Corp | 15.3M | -0.9x | --- |
BetterLife Pharma Inc | 13.6M | -2.9x | --- |
Company Information
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
Contact Information
- Headquarters
- First Canadian Place 100 King Street West, Suite 4000TORONTO, ON, Canada M5X 1A4
- Phone
- 416-854-8884
- Fax
- 416-854-8884
Executives
- Co-Executive Chairman of the Board
- Anthony Durkacz
- Chief Executive Officer, Director
- Zeeshan Saeed
- Chief Financial Officer
- Nathan Coyle
- Chief Executive Officer of Lucid, Director
- Lakshmi Kotra
- Chief Operating Officer
- Donal Carroll
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $13.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.9M |
Quantum BioPharma Ltd does not pay a dividend. | |
Beta | 0.83 |
EPS | $-22.02 |
Book Value | $30.53 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
